^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Kaitanni (cadonilimab) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A randomized, controlled, double-blind, multicenter phase II clinical study of PD-1/CTLA-4 dual antibody combined with chemoradiotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma
Excerpt:
...Progression Free Survival - Progression Free Survival; Disease Objective Response Rate - Disease Objective Response Rate; Disease Control Rate - Disease Control Rate; Duration of Response - Duration of Response; Disease Free Survival - Disease Free Survival; Overall Survival - Overall Survival; Distance Metastasis Free Survival - Distance Metastasis Free Survival; Locoregional Relapse-Free Survival - Locoregional Relapse-Free Survival; Quality of Life - Quality of Life; Safety evaluation - Safety evaluation; Tumor mutation burden - Tumor mutation burden; PD-L1 expression - PD-L1 expression; Plasma EB virus DNA copy number - Plasma EB virus DNA copy number; Genetic biomarkers of gut microbes - Genetic biomarkers of gut microbes...
Trial ID:
Source:
Title:
436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
Published date:
11/09/2021
Excerpt:
AK104 demonstrated encouraging anti-tumor activity and favorable safety profile in pts with NPC who had disease progression after =2 prior lines of therapy. NPC pts with PD-L1–positive tumors receiving AK104 showed more benefits than those with PD-L1-negative tumors.
DOI:
http://dx.doi.org/10.1136/jitc-2021-SITC2021.436
Trial ID:
